CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
October 16, 2019
 CCTG IND232 (NCT02788773) - A Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer has been closed to accrual after the completion of target accrual. Read More |
Pharmacist Representative for the Lung Disease Site CommitteePublished: October 16, 2019Category: Group updates  The Pharmacist Network is actively seeking a volunteer as Pharmacist Representative for the Lung Disease Site Committee. The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at: Pharmacist Representatives on Disease Site Committees Read More |
An interview with CCTG Patient Representative Erwin WandererPublished: October 16, 2019Category: News  Erwin Wanderer is the CCTG Patient Representative on the Genito-Urinary Disease Site Committee and Executive Committees, he resides in Halifax, Nova Scotia and has been CCTG Patient Representative since 2015. Erwin says, "I believe that being involved in a clinical trial can sometimes give patients access to procedures and treatments that they may not have been part of their original options. Read More |
October 02, 2019
 CCTG SC.24, A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases, has been closed to accrual after the completion of target accrual. Although the trial is closed accrual, treatment and follow up of patients will continue according to the protocol. The purpose of this study is to find out if SBRT is better than CRT at controlling pain in the spine 3 months after receiving treatment. Read More |
 The CCTG IND.225 trial: A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker |
 The use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials Read More |
 This past weekend at the European Society for Medical Oncology congress in Barcelona, Spain, there were many poster presentations by CCTG researchers. Poster Discussion: CCTG IND 232 - Phase II Study of Durvalumab with or without Tremelimumab in Patients with mCRPC Read More |
Video Interview with Dr. Michael McKenzie - CCTG Supportive Care CommitteePublished: October 02, 2019Category: News  Dr. McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology. He currently works as a radiation oncologist at BC Cancer Vancouver. He also is the co-chair of the CCTG Supportive Care Committee. In this video, McKenzie addresses the wide variety of trials the Supportive Care Committee is involved with, as well as potential avenues for new trials that may extend beyond the jurisdiction of cancer research. Read More |